Last reviewed · How we verify

NCT03675711: MIDREA

Midline Catheter and Its Impact on Central Lines Removal in ICU

Terminated NA Last updated 22 March 2023
What this trial tests

NA trial testing Midline in Vascular Access Device in 83 participants. Terminated before completion.

Timeline
2 November 2018
Primary endpoint
3 January 2023
13 January 2023

Quick facts

Lead sponsorCentre Hospitalier Departemental Vendee
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment83
Start date2 November 2018
Primary completion3 January 2023
Estimated completion13 January 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Departemental Vendee

Who can join

18 and older, any sex, with Vascular Access Device. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will evaluate 2 strategies to remove central venous catheter (CVC): in one part, the insertion of a midline catheter and in the other part, the conventional insertion of peripheral venous catheter (PVC)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Midline

Trials testing the same drug.

Other recruiting trials for Vascular Access Device

Currently open trials in the same condition.

Other Centre Hospitalier Departemental Vendee trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03675711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing